Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Enterprise Value: 2022-2025

Historic Enterprise Value for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $697.0 million.

  • Phathom Pharmaceuticals' Enterprise Value fell 5.80% to $697.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year increase of 111.77%. This contributed to the annual value of $255.1 million for FY2024, which is 84.24% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Enterprise Value is $697.0 million, which was up 34.79% from $517.1 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Enterprise Value's 5-year high stood at $739.9 million during Q3 2024, with a 5-year trough of $121.9 million in Q2 2022.
  • Moreover, its 3-year median value for Enterprise Value was $323.8 million (2024), whereas its average is $373.3 million.
  • Examining YoY changes over the last 5 years, Phathom Pharmaceuticals' Enterprise Value showed a top increase of 207.85% in 2023 and a maximum decrease of 55.49% in 2023.
  • Phathom Pharmaceuticals' Enterprise Value (Quarterly) stood at $311.1 million in 2022, then crashed by 55.49% to $138.5 million in 2023, then spiked by 84.24% to $255.1 million in 2024, then declined by 5.80% to $697.0 million in 2025.
  • Its Enterprise Value stands at $697.0 million for Q3 2025, versus $517.1 million for Q2 2025 and $221.4 million for Q1 2025.